NASDAQ · CING
Cingulate Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CING: Nov 12, 2026
Cingulate Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 4 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.48. The reported EPS for the same quarter last year was $-1.35.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.48 | $-0.39 | $-0.56 | 4 |
| Dec 2026 | $-0.32 | $0.05 | $-0.54 | 4 |
| Mar 2027 | $-0.21 | $0.16 | $-0.40 | 3 |
| Jun 2027 | $-0.12 | $0.40 | $-0.40 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel · The Motley Fool- RTTNews · Jun 5, 10:26 AM EDTWeekly Buzz: PHG, KMDA Win FDA Nod; FULC Halts Pociredir; RMD Closes Noctrix Deal; NVS Paces In IgAN(RTTNews) – This week, the biotech sector saw a wave of regulatory approvals in the U.S., alongside study halts, strategic collaborations, acquisitions, deal closures, and encouraging data readouts. Positive clinical study data readouts spanned multiple therapeutic areas, inclu
- RTTNews · Jun 3, 10:38 PM EDTTop Biotech Gainers: ABVX, CING, DRTS, MMED…(RTTNews) – Today's gainers list includes ABIVAX, which recently announced positive ulcerative colitis trial results; Cingulate, which is working toward resubmission of a New Drug Application for an ADHD therapy; and Alpha Tau, following its joint partnership with Tolmar to bring
- RTTNews · Jun 2, 10:11 PM EDTTop Biotech Gainers: PMI Advances Artificial Heart, CUE Makes Board Changes, CING Up Despite CRL(RTTNews) – Tuesday's top gainers in the healthcare sector included Bluejay Diagnostics, which inked a strategic partnership with Argonaut; Picard Medical, which is advancing its next-generation Emperor Total Artificial Heart; and Cingulate, which rallied despite a regulatory set
- RTTNews · Jun 2, 10:26 AM EDTFDA Issues CRL To Cingulate Requesting CMC Information On ADHD Drug CTx-1301; Stock Up(RTTNews) – Cingulate Inc. (CING), a biopharmaceutical company, on Tuesday announced receipt of a complete response letter (CRL) from the FDA regarding CTx-1301 for the treatment of attention deficit/hyperactivity disorder.
- RTTNews · Jun 2, 8:28 AM EDTCingulate Receives FDA Complete Response Letter For ADHD Drug CTx-1301(RTTNews) – Cingulate Inc. (CING) on Tuesday said the U.S. Food and Drug Administration has issued a Complete Response Letter for its New Drug Application seeking approval of CTx-1301 for the treatment of Attention Deficit/ Hyperactivity Disorder (ADHD).
- RTTNews · Apr 28, 8:01 AM EDTBiotech Stocks Facing FDA Decision In May 2026(RTTNews) – In the U.S., May is observed as Mental Health Awareness Month, a tradition that goes back to 1949. About 60 million American adults live with some form of mental illness, ranging from mild anxiety and depression to more severe psychiatric conditions, according to repo
- RTTNews · Jan 22, 11:42 PM ESTBiotech Sector Sees Broad After-Hours Gains Amid Quiet News Flow(RTTNews) – Biotech stocks saw notable upward momentum in Thursday's after-hours trading session, with several names posting strong percentage gains despite the absence of fresh company-specific developments.
- Fintel · Dec 8, 7:04 AM ESTAscendiant Capital Maintains Cingulate (CING) Buy RecommendationFintel reports that on December 8, 2025, Ascendiant Capital maintained coverage of Cingulate (NasdaqCM:CING) with a Buy recommendation. Analyst Price Forecast Suggests 620.90% Upside
- Fintel · Nov 19, 3:55 PM ESTRoth Capital Maintains Cingulate (CING) Buy RecommendationFintel reports that on November 19, 2025, Roth Capital maintained coverage of Cingulate (NasdaqCM:CING) with a Buy recommendation. Analyst Price Forecast Suggests 817.40% Upside
- RTTNews · Oct 24, 12:20 AM EDTINBX Soars 81% Post-Study; FEMY, CING, CYH Pop After Hours(RTTNews) – Biotech stocks led the after-hours charge on Thursday, with Inhibrx Biosciences (INBX) skyrocketing over 81% on positive Phase 2 trial results in chondrosarcoma. Femasys (FEMY), Cingulate (CING), and Community Health Systems (CYH) also posted notable gains, driven by
- RTTNews · Oct 14, 9:52 AM EDTFDA Accepts Cingulate's NDA For ADHD Candidate CTx-1301(RTTNews) – Cingulate Inc. (CING), a biopharmaceutical company, on Tuesday said the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for CTx-1301, the company's lead candidate for treating Attention-Deficit/Hyperactivity Disorder (ADHD) in child
- The Motley Fool · Aug 19, 1:58 PM EDTCingulate Posts Wider Loss in Q2Cingulate submitted its New Drug Application (NDA) for CTx-1301 to the FDA, targeting the ADHD market, with an NDA acceptance decision expected in late 2025.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Cingulate Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.